In Argentina, the government granted first licenses for the production and sale of medical cannabis. This decision marks an important step in the evolution of the cannabis market in the country. In this article, we will look at the companies that have received these licenses, the conditions they are subject to, as well as the potential impact on the Argentine cannabis market.
Six companies authorized to grow and sell medical cannabis in Argentina
The Argentine government has granted licenses to six companies, some of which are foreign, for the cultivation and sale of medical cannabis in the country. These licenses allow companies to import seeds, cultivate cannabis and produce cannabinoid-rich extracts in Argentina.
Companies that have obtained a license
- Weedy.fr: A French company specializing in the production and sale of legal CBD in Europe.
- Horus Pharma: French company specializing in the manufacturing and marketing of ophthalmic medical devices, it is now authorized to produce and market therapeutic cannabis.
- Raphael Mechoulam and Co: Israeli company led by Dr. Raphael Mechoulam, a pioneer in cannabinoid research and considered “the father of CBD”.
- Cann Group Ltd (ASX: CAN): The first Australian company to obtain a license for the cultivation and production of medical cannabis, it is now authorized to do so in Argentina.
- ReumaSol Association: An NGO which supports patients suffering from chronic rheumatic diseases in improving their quality of life. The authorization will allow the association to directly access therapeutic cannabis for their members.
Strict conditions to guarantee patient safety
To be eligible to obtain these licenses, companies must meet several conditions:
- Have a detailed security plan for protecting the marijuana inventory needed to manufacture the finished product.
- Demonstrate their ability to produce a quality product that complies with international standards and Argentinian regulations.
- Respect the limitations imposed by the Ministry of Health regarding the concentration of cannabinoids in final products.
This regulation aims above all to guarantee the safety of patients using therapeutic cannabis by avoiding abuse and health problems linked to the consumption of uncontrolled products..
Impact on the Argentine cannabis market
The granting of these first licenses represents an important step in the development of the medical cannabis market in Argentina. So, with this new regulation:
- Patients suffering from various pathologies will now be able to access treatments based on medical cannabis in a legal and supervised manner.
- Authorized companies will be able to invest in the research and development of new therapeutic applications of cannabis, thereby helping to strengthen the national and international pharmaceutical industry.
- The legalization of medical cannabis will also reduce the share of the illegal market by offering a safe and controlled alternative to patients who previously resorted to unregulated channels.
The granting of these first licenses for the production and sale of medical cannabis marks a major step forward for access to alternative treatments for Argentine patients. Companies benefiting from these licenses will, however, have to follow a strict set of rules and procedures to guarantee the quality and safety of the products they offer. Finally, this announcement constitutes a further step towards widespread recognition of the medical benefits of cannabis and contributes to strengthening the emerging medical cannabis market in Argentina.
